Equities

Viridian Therapeutics Inc

Viridian Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.21
  • Today's Change0.50 / 2.02%
  • Shares traded889.41k
  • 1 Year change+79.05%
  • Beta1.1079
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

  • Revenue in USD (TTM)288.00k
  • Net income in USD-228.06m
  • Incorporated2010
  • Employees96.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Intellia Therapeutics Inc43.09m-522.28m1.70bn526.00--1.77--39.44-5.45-5.450.45099.460.0357--5.6281,912.55-43.22-31.34-47.07-34.53-----1,212.19-654.71----0.00---30.403.57-1.48--17.08--
Dynavax Technologies Corp249.70m17.18m1.70bn408.00128.672.6578.696.830.10110.10111.764.910.25570.77664.76611,997.601.764.161.865.7182.0364.836.889.1913.18--0.25780.00-67.8695.19-102.18---23.03--
Bicycle Therapeutics PLC (ADR)36.90m-166.28m1.72bn284.00--2.07--46.71-3.28-3.280.716312.040.0451--0.9806129,922.50-20.33-29.45-22.03-32.98-----450.64-571.36----0.0002--86.5230.47-60.28--19.82--
Celldex Therapeutics, Inc.9.98m-154.08m1.74bn160.00--2.21--174.37-2.57-2.570.16411.850.0181--18.0762,350.00-27.93-29.65-29.53-31.42-----1,544.48-1,747.94----0.00--192.02-6.32-25.91--17.46--
Syndax Pharmaceuticals Inc16.00m-297.06m1.86bn112.00--5.09--116.35-3.63-3.630.19494.280.0388--3.60142,857.10-72.01-27.90-81.78-30.15-----1,856.64-324.34----0.00003-------40.19------
Arvinas Inc161.10m-308.60m1.86bn445.00--3.18--11.58-4.79-4.792.388.530.1448--14.01362,022.50-27.73-22.01-37.81-26.47-----191.56-316.55----0.001---40.2640.53-30.02--0.4852--
Viridian Therapeutics Inc288.00k-228.06m1.92bn96.00--4.89--6,682.95-4.25-4.250.00538.290.0006--5.653,063.83-48.67-55.59-52.32-60.32-----79,185.77-5,678.12----0.0372---82.28-48.16-83.05--15.08--
Disc Medicine Inc0.00-91.00m1.93bn74.00--3.95-----3.66-3.660.0016.450.00----0.00-20.35---21.06--------------0.00-------63.22------
Nurix Therapeutics Inc56.42m-176.98m1.94bn284.00--4.87--34.32-2.91-2.910.92225.620.1373----198,676.10-43.07-33.01-52.51-39.66-----313.65-260.65----0.00--99.3115.5020.19--39.42--
Mirum Pharmaceuticals Inc264.38m-109.16m2.00bn294.00--8.73--7.58-2.40-2.405.814.810.47885.065.521,001,424.00-19.77-38.93-23.38-44.8872.27---41.29-190.713.09--0.573--141.85---20.45--21.81--
Spyre Therapeutics Inc0.00-185.98m2.01bn50.00--9.20-----15.42-15.420.007.370.00----0.00-54.73-101.87-87.47-118.83-------2,949.59----0.00---61.96-25.61-304.21------
MannKind Corp248.37m11.74m2.02bn414.00204.77--116.648.130.03590.03590.834-0.82260.6562.859.71599,937.203.10-26.074.05-37.8071.2959.684.73-57.613.761.861.89--99.4248.1786.34--160.47--
Recursion Pharmaceuticals Inc65.18m-377.75m2.04bn500.00--3.87--31.22-1.53-1.530.26311.830.096--24.06130,368.00-55.66---65.45--35.07---579.51------0.0519--11.88---36.99------
Fortrea Holdings Inc2.88bn-228.20m2.11bn16.00k--1.44--0.732-2.56-3.2332.3016.330.7262--3.48159,794.40-5.76---7.11--17.17---7.93-----0.33740.4348--0.4167---101.76------
Data as of Nov 08 2024. Currency figures normalised to Viridian Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

47.35%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 20248.15m10.68%
BlackRock Fund Advisorsas of 30 Jun 20244.31m5.64%
Deep Track Capital LPas of 30 Jun 20243.92m5.14%
Fairmount Funds Management LLCas of 13 Sep 20243.45m4.51%
Maverick Capital Ltd.as of 30 Jun 20243.31m4.33%
The Vanguard Group, Inc.as of 30 Jun 20243.21m4.21%
Paradigm BioCapital Advisors LPas of 30 Jun 20242.90m3.79%
Commodore Capital LPas of 30 Jun 20242.53m3.31%
SSgA Funds Management, Inc.as of 30 Sep 20242.38m3.12%
AllianceBernstein LPas of 30 Jun 20242.00m2.62%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.